Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
South Korean military plans to launch new division for future warfare
-
7
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
SK Networks Co., the general trading arm of South Korean conglomerate SK Group, said Friday it has invested $20 million in a US biotech startup specializing in making alternative leather.
SK Networks took part in a round of $126 million funding for MycoWorks, a Silicon Valley-based biomaterials company, and it is the largest amount among the strategic investors, SK said in a press release.
MycoWorks owns technologies that produce leather-like fabric from engineered mycelium, a biomaterial made out of mushrooms. The company has also partnered up with Hermes and a number of other major global luxury brands.
The two companies also signed a separate contract to cooperate on the development of new materials, production expansion and building a sales network.
Bio business is one of SK's four core areas it has been expanding as its future growth drivers, including biopharmaceuticals and biodegradable materials. (Yonhap)
SK Networks took part in a round of $126 million funding for MycoWorks, a Silicon Valley-based biomaterials company, and it is the largest amount among the strategic investors, SK said in a press release.
MycoWorks owns technologies that produce leather-like fabric from engineered mycelium, a biomaterial made out of mushrooms. The company has also partnered up with Hermes and a number of other major global luxury brands.
The two companies also signed a separate contract to cooperate on the development of new materials, production expansion and building a sales network.
Bio business is one of SK's four core areas it has been expanding as its future growth drivers, including biopharmaceuticals and biodegradable materials. (Yonhap)
